PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and VP-002, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for retinal and central nervous system diseases. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
| 0.0617 | |
| 0.0617 | |
| - | |
| 0.0617 | |
| 0.0617 | |
| 0.0617-0.065 | |
| 284 M | |
| 3 181 M | |
| 3 074 K | |
| 0.3077 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Every investor in PYC Therapeutics Limited (ASX:PYC) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conver...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose mone...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
